ROSEWOOD Trial

ROSEWOOD (NCT03332017) is a Phase 2, open-label, randomized trial of zanubrutinib combined with obinutuzumab compared with obinutuzumab monotherapy in patients with relapsed/refractory (R/R) follicular lymphoma (FL).